3 completed, 2 terminated, 1 unknown. 2 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow lenzilumab: new trials by email Literature Review of lenzilumab trials Research Report on lenzilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; Interferon alfa, Selinexor, Lenzilumab - Cancer, Covid19 | Phase 3 | Completed | Peter MacCallum Cancer Centre, Australia | 441 | 2020-12-17 | 2023-08-24 |
| ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 Lenzilumab, Placebo, Remdesivir - COVID-19 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 527 | 2020-10-23 | 2023-06-05 |
| Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma Cyclophosphamide, Fludarabine, Lenzilumab - Relapsed/Refractory Large B-cell Lymphoma | Phase 1 | Terminated | Kite, A Gilead Company | 6 | 2020-05-26 | 2024-03-04 |
| Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 Lenzilumab, Standard of Care - Coronavirus Disease 2019 (COVID-19) Pneumonia | Phase 3 | Unknown | Humanigen, Inc. | 520 | 2020-05-05 | 2021-03-03 |
| Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) lenzilumab - Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Completed | Humanigen, Inc. | 15 | 2016-07-01 | 2020-02-28 |
| Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis KB003, Placebo Comparator - Rheumatoid Arthritis | Phase 2 | Terminated | Humanigen, Inc. | 9 | 2010-01-01 | 2014-06-09 |
COVID-19 (3) · Arthritis, Rheumatoid (1) · Cytokine Release Syndrome (1) · Leukemia, Myelomonocytic, Chronic (1) · Neoplasms (1) · Pneumonia (1) · Recurrence (1)
Humanigen, Inc. (3) · Kite, A Gilead Company (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Peter MacCallum Cancer Centre, Australia (1)
United States (5) · Australia (1) · Brazil (1) · South Korea (1)
Cameron Durrant, MD (1) · Nestor A. Molfino, MD, MSC (1)
PMID 34473343, PMID 33153629, PMID 33673929, PMID 33972949, PMID 34863332, PMID 35793833, PMID 40874769
2019 (1)